KIMBERLY MANHARD - 03 May 2022 Form 4 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)

Role
EVP, Drug Development, Director
Signature
/s/ Lisa Peraza Attorney-in-fact for Kimberly Manhard
Issuer symbol
HRTX
Transactions as of
03 May 2022
Net transactions value
-$1,375
Form type
4
Filing time
04 May 2022, 19:01:26 UTC
Previous filing
15 Apr 2022
Next filing
26 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRTX Common Stock Other $5,778 +1,504 +14% $3.84 12,376 29 Apr 2022 Direct F1
transaction HRTX Common Stock Sale $7,154 -1,504 -12% $4.76 10,872 03 May 2022 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 29, 2022.
F2 The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of September 13, 2021.
F3 The range of sales prices received was $4.695 to $4.835. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.